Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer

doi:10.12998/wjcc.122960

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 23

This Article

(15)

(16)

(0)

(9)

(228)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Cases. Aug 16, 2026; 14(23): 122960
Published online Aug 16, 2026. doi: 10.12998/wjcc.122960

Full Size Figure Download Figure

Figure 3 Comparison of rescue medication use over 5 days post concurrent chemoradiotherapy in both the antiemetic regimen groups. CCRT: Concurrent chemoradiotherapy.

Citation: Gupta N, Sehgal S, Mittal N. Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer. World J Clin Cases 2026; 14(23): 122960
URL: https://www.wjgnet.com/2307-8960/full/v14/i23/122960.htm
DOI: https://dx.doi.org/10.12998/wjcc.122960